| Literature DB >> 35011823 |
Carlos Bernal-Utrera1,2, Ernesto Anarte-Lazo3, Juan Jose Gonzalez-Gerez2,4, Manuel Saavedra-Hernandez2,4, Elena De-La-Barrera-Aranda2,5, Maria Angeles Serrera-Figallo6, Maribel Gonzalez-Martin6, Cleofas Rodriguez-Blanco1,2.
Abstract
Postural stability is a little-studied factor in non-specific chronic neck pain; the causes that can alter it are unknown. The relationship with chronic pain could be a determining factor for its deficit. The aim of this study was to investigate the relationship between sustained pain and a postural stability deficit. A randomized and blinded clinical trial (double-blind; placebo control; 12 weeks follow-up) was conducted with a total of 69 subjects divided into three groups, two experimental (manual therapy and specific exercise) and a control treatment, and carried out over a treatment period of three weeks with a follow-up after 12 weeks. Their postural stability was assessed through the overall balance index (OBI). The postural stability of subjects with non-specific chronic neck pain improved in the experimental treatments. There were no statistically significant differences between the experimental groups. This trial found that manual therapy and therapeutic exercise significantly improved OBI compared to the control group. Trial registration: Brazilian Clinical Trial Registry, RBR-2vj7sw.Entities:
Keywords: chronic pain; exercise therapy; musculoskeletal manipulations; neck pain; postural stability
Year: 2021 PMID: 35011823 PMCID: PMC8745098 DOI: 10.3390/jcm11010084
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Manual Therapy Protocol. (A) Cervical Articular Mobilization, (B) High Thoracic Manipulation on T4, (C) Suboccipital Muscle Inhibition.
Figure 2Examples of therapeutic exercises.
Figure 3Biodex Balance System ™ SD.
Figure 4CONSORT Flows Diagram.
Participants’ baseline characteristics according to the study group.
| VARIABLES | GROUP | Z | ||
|---|---|---|---|---|
| MT | TE | C |
| |
| Age (i) | 42.95 ± 2.89 | 36.78 ± 2.89 | 36.90 ± 2.89 | 0.312 b |
| Gender (ii) | 23 (5/22); | 22 (5/23); | 29 (6/21); | 0.315 c |
| Body Mass Index (i) (Kg/m) | 24.67 ± 1.13 | 23.8 ± 0.72 | 24.75 ± 0.75 | 0.379 b |
| VAS (i) (mm) | 41.95 ± 4.03 | 48.17 ± 3.48 | 49.80 ± 3.53 | 0.237 b |
| OBI (i) | 6.34 ± 0.77 | 4.95 ± 0.59 | 5.47 ± 0.64 | 0.498 b |
C: Control Group; MT: Manual Therapy Group; TE: therapeutic exercise group; Z: Shapiro–Wilk normality test; p: statistical significance; a: ANOVA; b: H Kruskal–Wallis; c: Chi Cuadrado; (i) dates expressed as means ± standard deviation; (ii) dates expressed as percentages (partial/total); * Indicate statistically significant differences between groups (p < 0.05).
Intergroup analysis for VAS.
| VAS Pre (i) | VAS Week 1 (i) |
| VAS Week 4 (i) |
| VAS Week 12 (i) |
| |
|---|---|---|---|---|---|---|---|
| MT | 41.95 ± 4.03 | 32.77 ± 3.14 | 0.007 * b | 15.82 ± 3.26 | 0.001 * b | 18.23 ± 4.33 | 0.002 * b |
| TE | 48.17 ± 3.48 | 35.83 ± 3.88 | 0.008 * a | 17.83± 3.42 | 0.001 * b | 24.43 ± 4.70 | 0.002 * b |
| C | 49.80 ± 3.53 | 49.25 ± 3.53 | 0.342 a | 50.55 ± 3.54 | 0.518 a | 48.75 ± 3.51 | 0.337 a |
C: control group; MT: manual therapy group; TE: therapeutic exercise group; p: statistical significance from tests: a: t student for paired samples; b: Z Wilcoxon; (i) dates expressed as means ± standard deviation; * Indicate statistically significant differences between groups (p < 0.05).
Intergroup analysis for OBI.
| OBI Pre (i) |
OBI |
|
OBI |
|
OBI |
| |
|---|---|---|---|---|---|---|---|
| MT | 6.34 ±0.77 | 4.87 ± 0.64 | 0.001 * b | 4.01 ± 0.47 | 0.001 * b | 4.77 ± 0.65 | 0.003 * b |
| TE | 4.95 ±0.59 | 3.91 ± 0.41 | 0.017 * b | 4.06 ±0.73 | 0.013 * b | 3.83 ± 0.47 | 0.010 * b |
| C | 5.47 ±0.64 | 5.42 ± 0.62 | 0.808 b | 5.47 ± 0.66 | 0.745 b | 5.43 ± 0.62 | 0.579 b |
C: control group; MT: manual therapy group; TE: therapeutic exercise group; p: statistical significance from tests: b: Z Wilcoxon; (i) dates expressed as means ± standard deviation; * Indicate statistically significant differences between groups (p < 0.05).
Intergroup Analysis.
| VARIABLE |
| Post hoc |
|
| Post hoc |
|
| Post hoc |
|
|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 4 | Week 12 | M and CI | ||||||
| VAS | 0.067 a | MT–C | 0.0329 c | 0.001 a | MT–C | 0.001 * c | 0.003 a | MT–C | 0.008 * c |
| 7.61 | 26.71 | 22.77 | |||||||
| [−3.92 to 19.14] | [12.30 to 41.11] | [4.79 to 40.76] | |||||||
| TE–C | 0.070 c | TE–C | 0.001 * c | TE–C | 0.007 * c | ||||
| 10.77 | 30.92 | 22.79 | |||||||
| [−0.64 to 22.19] | [16.67 to 45.17] | [5.00 to 40.58] | |||||||
| MT–TE | 1.000 c | MT–TE | 1.000 c | MT–TE | 1.000 c | ||||
| 3.17 | −4.21 | −0.01 | |||||||
| [−14.44 to 8.11] | [−18.29 to 9.87] | [−17.59 to 17.56] | |||||||
| OBI | 0.003 * b | MT–C | 0.001 * d | 0.001 * b | MT–C | 0.001 * d | 0.013 * b | MT–C | 0.006 * d |
| 1.41 | 2.30 | 1.53 | |||||||
| [0.32 to 2.50] | [0.98 to 3.63] | [0.22 to 2.83] | |||||||
| TE–C | 0.116 d | TE–C | 0.013 * d | TE–C | 0.028 * d | ||||
| 0.99 | 0.88 | 1.08 | |||||||
| [−0.09 to 2.06] | [−0.44 to 2.19] | [−0.21 to 2.38] | |||||||
| MT–TE | 0.261 d | MT–TE | 0.064 d | MT–TE | 0.420 d | ||||
| 0.42 | 1.43 | 0.44 | |||||||
| [−0.64 to 1.49] | [0.13 to 2.73] | [−0.84 to 1.72] |
C: Control Group; MT: Manual Therapy Group; TE: Therapeutic Exercise Group; p: Significación Estadística; M: Mean Diference; CI: Confidence Interval; a: ANOVA; b: H Kruskal-Wallis, c: Bonferroni, d: U Mann-Whitney; * Indicate statistically significant differences between groups (p < 0.05).